iCAD Inc. (NASDAQ:ICAD) announced financial results for the fourth quarter and year ending December 31st. Revenue growth momentum continues as does improvement in operating income. Revenue and operating income for both Q4 and the full-year were the highest for each respective period since 2008. This is the highest since acquiring Xoft in December 2010. The Xoft acquisition brought with it the Axxent System, an electronic brachytherapy device used for the treatment of cancer. The initial target market was for intraoperative radiation therapy (IORT) for breast cancer but use for non-melanoma skin cancer has quickly become the driving force behind ICAD's recently ramping revenues.
Much of the growth continues to come from the Cancer Therapy business and, in particular,
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|